Anti-Rotavirus (Clone: RV6-25) – Purified No Carrier Protein

Anti-Rotavirus (Clone: RV6-25) – Purified No Carrier Protein

Product No.: LT582

- -
- -
Product No.LT582
Clone
RV6-25
Target
Rotavirus
Product Type
Recombinant Monoclonal Antibody
Isotype
Human IgG
Applications
ELISA
,
FC
,
Lateral Flow

- -
- -
Select Product Size

Data

Lateral flow LOD testing of rotavirus antibodies RV6-25 and RV6-26.
- -
- -

Antibody Details

Product Details

Reactive Species
Rotavirus
Virus
Expression Host
HEK-293 Cells
Immunogen
Human Mab RV6-25 was sequenced from RV-specific B cells isolated from the blood of healthy adult donors or RV-infected infants or adults5,6.
Product Concentration
≥1.0 mg/ml
Purity
>90% monomer by analytical SEC and SDS-Page
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Standard Overnight on Blue Ice.
Applications and Recommended Usage?
Quality Tested by Leinco
Lateral Flow
Additional Applications Reported In Literature ?
ELISA
N
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
RV6-25 activity is directed against the apical surface of the VP6 head domain. RV6-25 and RV6-26 are encoded by the same heavy chain variable segment6, but unlike RV6-26, RV6-25 is unable to inhibit RV5. Three-dimensional structural analyses of DLP: Fab complexes show that RV6-25 Fab molecules attach to the tops of VP6 trimers, at one VP6 subunit, with the epitope positioned along the edge and in close contact with the VP6 surface loop5. The RV6-25 Fab protrudes from the VP6 trimers and extends away from the viral surface in a regular pattern depending on the position of the VP6 trimer in the VP6 layer1. Additionally, RV6-25 binds to the apical surface of the DLP VP6 head domain and does not obstruct the transcription pore1. The Fab binds to epitopes on the distinct P, P′, T, T′, or D VP6 trimers.
Background
Rotaviruses (RV) are double-stranded, non-enveloped, icosahedral RNA viruses in the Reoviridae family1 that cause severe dehydrating diarrhea in infants and children2. RV particles are composed of concentric viral protein (VP) layers3. The triple-layered particle has an inner capsid layer (VP2), an intermediate capsid layer (VP6), and an outer capsid layer (VP7, VP4). The transcriptionally active double-layered particle (DLP) consists of VP2 and VP6. VP6 is the most antigenic RV protein in humans4.

Matched Pair
This antibody has been tested in lateral flow assays. The best matched pair is RV6-25 (Capture)/RV6-26 (Detection).
Research Area
Infectious Disease
.
Matched Pair
.
Rotavirus
.
Viral
.
IVD Raw Material

References & Citations

1. Aiyegbo MS, Eli IM, Spiller BW, et al. J Virol. 88(1):469-76. 2014.
2. Bern C, Martines J, de Zoysa I, et al. Bull World Health Organ. 70: 705-714. 1992.
3. Pesavento, JB, Crawford SE, Estes MK, et al. Curr Top Microbiol Immunol. 309: 189-219. 2006.
4. McKinney BA, Kallewaard NL, Crowe JE, et al. Immunome Res 3:8. 2007.
5. Kallewaard NL, McKinney BA, Gu Y, et al. J Immunol. 180(6):3980-9. 2008.
6. Weitkamp JH, Kallewaard NL, Bowen AL, et al. J Immunol. 174(6):3454-60. 2005.
7. Weitkamp JH, Kallewaard N, Kusuhara K, et al. J Immunol Methods. 275:223–237. 2003.
Indirect Elisa Protocol
Flow Cytometry
Lateral Flow

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.